Literature DB >> 21238599

Phylogenetic lineage and pilus protein Spb1/SAN1518 affect opsonin-independent phagocytosis and intracellular survival of Group B Streptococcus.

Debasish Chattopadhyay1, Alison J Carey2, Elise Caliot3, Richard I Webb4, James R Layton5, Yan Wang6, John F Bohnsack7, Elisabeth E Adderson6, Glen C Ulett1,2.   

Abstract

Opsonin-independent phagocytosis of Group B Streptococcus (GBS) is important in defense against neonatal GBS infections. A recent study indicated a role for GBS pilus in macrophage phagocytosis (Maisey et al Faseb J 22 2008 1715-24). We studied 163 isolates from different phylogenetic backgrounds and those possessing or lacking the gene encoding the pilus backbone protein, Spb1 (SAN1518, PI-2b) and spb1-deficient mutants of wild-type (WT) serotype III-3 GBS 874391 in non-opsonic phagocytosis assays using J774A.1 macrophages. Numbers of GBS phagocytosed differed up to 23-fold depending on phylogenetic background; isolates possessing spb1 were phagocytosed more than isolates lacking spb1. Comparing WT GBS and isogenic spb1-deficient mutants showed WT was phagocytosed better compared to mutants; Spb1 also enhanced intracellular survival as mutants were killed more efficiently. Complementation of mutants restored phagocytosis and resistance to killing in J774A.1 macrophages. Spb1 antiserum revealed surface expression in WT GBS and spatial distribution relative to capsular polysaccharide. spb1 did not affect macrophage nitric oxide and TNF-alpha responses; differences in phagocytosis did not correlate with N-acetyl d-glucosamine (from GBS cell-wall) according to enzyme-linked lectin-sorbent assay. Together, these findings support a role for phylogenetic lineage and Spb1 in opsonin-independent phagocytosis and intracellular survival of GBS in J774A.1 macrophages.
Copyright © 2011. Published by Elsevier SAS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21238599      PMCID: PMC4500112          DOI: 10.1016/j.micinf.2010.12.009

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  52 in total

1.  Mechanisms of group B streptococcal-induced apoptosis of murine macrophages.

Authors:  Glen C Ulett; Kirsteen H Maclean; Sunitha Nekkalapu; John L Cleveland; Elisabeth E Adderson
Journal:  J Immunol       Date:  2005-08-15       Impact factor: 5.422

2.  Illustration of pneumococcal polysaccharide capsule during adherence and invasion of epithelial cells.

Authors:  Sven Hammerschmidt; Sonja Wolff; Andreas Hocke; Simone Rosseau; Ellruth Müller; Manfred Rohde
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

3.  The SrtA Sortase of Streptococcus agalactiae is required for cell wall anchoring of proteins containing the LPXTG motif, for adhesion to epithelial cells, and for colonization of the mouse intestine.

Authors:  Lila Lalioui; Elisabeth Pellegrini; Shaynoor Dramsi; Marina Baptista; Nadege Bourgeois; Florence Doucet-Populaire; Christophe Rusniok; Mohamed Zouine; Philippe Glaser; Frank Kunst; Claire Poyart; Patrick Trieu-Cuot
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

4.  Human alveolar and peritoneal macrophages mediate fungistasis independently of L-arginine oxidation to nitrite or nitrate.

Authors:  M L Cameron; D L Granger; J B Weinberg; W J Kozumbo; H S Koren
Journal:  Am Rev Respir Dis       Date:  1990-12

5.  Group B streptococci persist inside macrophages.

Authors:  P Cornacchione; L Scaringi; K Fettucciari; E Rosati; R Sabatini; G Orefici; C von Hunolstein; A Modesti; A Modica; F Minelli; P Marconi
Journal:  Immunology       Date:  1998-01       Impact factor: 7.397

Review 6.  Group B streptococcal infections in elderly adults.

Authors:  Morven S Edwards; Carol J Baker
Journal:  Clin Infect Dis       Date:  2005-08-16       Impact factor: 9.079

7.  Nitric oxide synthase is not a constituent of the antimicrobial armature of human mononuclear phagocytes.

Authors:  M Schneemann; G Schoedon; S Hofer; N Blau; L Guerrero; A Schaffner
Journal:  J Infect Dis       Date:  1993-06       Impact factor: 5.226

8.  Identification of a high-virulence clone of type III Streptococcus agalactiae (group B Streptococcus) causing invasive neonatal disease.

Authors:  J M Musser; S J Mattingly; R Quentin; A Goudeau; R K Selander
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

9.  UpaG, a new member of the trimeric autotransporter family of adhesins in uropathogenic Escherichia coli.

Authors:  Jaione Valle; Amanda N Mabbett; Glen C Ulett; Alejandro Toledo-Arana; Karine Wecker; Makrina Totsika; Mark A Schembri; Jean-Marc Ghigo; Christophe Beloin
Journal:  J Bacteriol       Date:  2008-04-18       Impact factor: 3.490

10.  Diversity of group B streptococcus serotypes causing urinary tract infection in adults.

Authors:  Kimberly B Ulett; William H Benjamin; Fenglin Zhuo; Meng Xiao; Fanrong Kong; Gwendolyn L Gilbert; Mark A Schembri; Glen C Ulett
Journal:  J Clin Microbiol       Date:  2009-05-13       Impact factor: 5.948

View more
  13 in total

1.  Differing mechanisms of surviving phagosomal stress among group B Streptococcus strains of varying genotypes.

Authors:  Michelle L Korir; Clare Laut; Lisa M Rogers; Jessica A Plemmons; David M Aronoff; Shannon D Manning
Journal:  Virulence       Date:  2016-10-28       Impact factor: 5.882

Review 2.  Intrinsic Maturational Neonatal Immune Deficiencies and Susceptibility to Group B Streptococcus Infection.

Authors:  Michelle L Korir; Shannon D Manning; H Dele Davies
Journal:  Clin Microbiol Rev       Date:  2017-10       Impact factor: 26.132

3.  Association and virulence gene expression vary among serotype III group B streptococcus isolates following exposure to decidual and lung epithelial cells.

Authors:  Michelle L Korir; David Knupp; Kathryn LeMerise; Erica Boldenow; Rita Loch-Caruso; David M Aronoff; Shannon D Manning
Journal:  Infect Immun       Date:  2014-08-18       Impact factor: 3.441

4.  Antimicrobial susceptibility profiles, serotype distribution and virulence determinants among invasive, non-invasive and colonizing Streptococcus agalactiae (group B streptococcus) from Malaysian patients.

Authors:  N Eskandarian; Z Ismail; V Neela; A van Belkum; M N M Desa; S Amin Nordin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-10-31       Impact factor: 3.267

5.  Regulation of PI-2b Pilus Expression in Hypervirulent Streptococcus agalactiae ST-17 BM110.

Authors:  Bruno Périchon; Noémi Szili; Laurence du Merle; Isabelle Rosinski-Chupin; Myriam Gominet; Samuel Bellais; Claire Poyart; Patrick Trieu-Cuot; Shaynoor Dramsi
Journal:  PLoS One       Date:  2017-01-20       Impact factor: 3.240

Review 6.  Novel Molecular Insights about Lactobacillar Sortase-Dependent Piliation.

Authors:  Ingemar von Ossowski
Journal:  Int J Mol Sci       Date:  2017-07-18       Impact factor: 5.923

7.  Molecular epidemiology of Streptococcus agalactiae isolated from mastitis in Brazilian dairy herds.

Authors:  Glei A Carvalho-Castro; Juliana R Silva; Luciano V Paiva; Dircéia A C Custódio; Rafael O Moreira; Glaucia F Mian; Ingrid A Prado; Antônio Chalfun-Junior; Geraldo M Costa
Journal:  Braz J Microbiol       Date:  2017-02-16       Impact factor: 2.476

Review 8.  Group B Streptococcal Colonization, Molecular Characteristics, and Epidemiology.

Authors:  Sarah Shabayek; Barbara Spellerberg
Journal:  Front Microbiol       Date:  2018-03-14       Impact factor: 5.640

9.  Pilus distribution among lineages of group b streptococcus: an evolutionary and clinical perspective.

Authors:  Amber Cody Springman; David W Lacher; Emily A Waymire; Samantha L Wengert; Pallavi Singh; Ruth N Zadoks; H Dele Davies; Shannon D Manning
Journal:  BMC Microbiol       Date:  2014-06-19       Impact factor: 3.605

10.  Contribution of pilus type 2b to invasive disease caused by a Streptococcus agalactiae ST-17 strain.

Authors:  Maddalena Lazzarin; Rong Mu; Monica Fabbrini; Claudia Ghezzo; C Daniela Rinaudo; Kelly S Doran; Immaculada Margarit
Journal:  BMC Microbiol       Date:  2017-07-03       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.